Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Core Insights - Merck & Co. has announced a $9.2 billion acquisition of Cidara Therapeutics, enhancing its respiratory portfolio [1] Company Summary - The acquisition is part of Merck's strategy to strengthen its position in the biotechnology sector, particularly in respiratory treatments [1] - Cidara Therapeutics is a biotechnology company that focuses on developing innovative therapies, which aligns with Merck's growth objectives [1] Industry Summary - This deal reflects a broader trend in the biotechnology industry where larger pharmaceutical companies are acquiring smaller firms to expand their product offerings and pipeline [1] - The respiratory market is increasingly competitive, and such acquisitions are crucial for companies like Merck to maintain a leading edge [1]